Lisata outlines Phase III certepetide trial preparations and targets milestone-rich 2026 amid expanded alliances
I'm PortAI, I can summarize articles.
Lisata Therapeutics (LSTA) CEO David Mazzo discussed the company's Phase III certepetide trial preparations during the Q3 2025 earnings call. He emphasized several development milestones, including positive preliminary results from the ASCEND, iLSTA, and CENDIFOX trials. The company aims for a milestone-rich 2026, supported by expanded alliances.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments